Novo shares slip even on positive pediatric data

Novo Nordisk reported results on September 7, 2026 from its STEP Young trial testing once-weekly semaglutide in children ages 6 to 11 with obesity. The stock still fell 1.92% that day, closing at $46.60 ^[1]. By September 11, shares had dropped further to $43.07, down 2.14% ^[2]. Analysts said the pediatric data was a real win but not enough on its own to reverse Novo Nordisk's recent market-share losses to rival Eli Lilly ^[2].

The trial enrolled 165 children in a randomized, double-blind, placebo-controlled study across multiple countries. More than 85% of participants had class II or class III severe obesity at the start ^[1]. Children received semaglutide, dosed by weight up to a maximum of 1.7 mg or 2.4 mg, or placebo, alongside a reduced-calorie diet and increased physical activity, for 68 weeks ^[1]. The trial met its main goal: semaglutide produced a bigger drop in body mass index than placebo ^[1].

By week 68, 40.4% of children on semaglutide no longer met the study's obesity classification, based on CDC age- and sex-specific BMI growth charts. None of the children on placebo crossed that line ^{[1] [2]}. Novo Nordisk said safety and tolerability matched earlier semaglutide and liraglutide studies, and researchers found no new concerns involving growth or pubertal development ^[1].

The company plans to present full results at ObesityWeek 2026 in Washington, D.C., from November 14 through 17 ^[1]. Novo Nordisk designed the trial to satisfy post-marketing requirements tied to its broader semaglutide development program, which already includes approvals in adults and adolescents 12 and older ^{[1] [2]}.

Why it matters for patients

Wegovy is currently approved in the United States for chronic weight management in adults and in adolescents 12 and older, but not in children younger than 12 ^[2]. If regulators approve semaglutide for ages 6 to 11 based on this data, it would open a new treatment option for a group that currently has few beyond diet and lifestyle changes. Eli Lilly's Zepbound does not yet have an indication for this age group ^[2].

The CDC found that 22.1% of children ages 6 to 11 were classified as obese between August 2021 and August 2023, a population of more than 20 million in the United States ^[2]. One analyst estimated the number of children in this age group with obesity at roughly 4 million, a smaller pool than semaglutide's adult market but not a small one ^[2]. Global estimates put the number of children ages 5 to 19 with obesity at 177 million in 2025, projected to reach 228 million by 2040 ^[1].

For families, the stock's decline despite positive trial results is a reminder that share price moves do not always track clinical progress. Novo Nordisk's broader challenges, including competition from Eli Lilly and questions about drug pricing, appear to be weighing more heavily on investors than a single successful trial ^[2]. That dynamic does not change what the trial found about safety or effectiveness, but it does suggest that any pediatric approval, if it comes, may take time to translate into a shift in the company's market position.

What happens next

Novo Nordisk is set to present full STEP Young data at ObesityWeek 2026 in Washington, D.C., from November 14 to 17, 2026 ^[1]. No timeline for a regulatory submission or approval decision for the 6-to-11 age group was included in the available reporting.